JP2020519676A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519676A5
JP2020519676A5 JP2019563255A JP2019563255A JP2020519676A5 JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5 JP 2019563255 A JP2019563255 A JP 2019563255A JP 2019563255 A JP2019563255 A JP 2019563255A JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5
Authority
JP
Japan
Prior art keywords
acting
long
receptor agonist
less
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563255A
Other languages
English (en)
Japanese (ja)
Other versions
JP7316222B2 (ja
JP2020519676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032817 external-priority patent/WO2018213341A1/en
Publication of JP2020519676A publication Critical patent/JP2020519676A/ja
Publication of JP2020519676A5 publication Critical patent/JP2020519676A5/ja
Priority to JP2023063333A priority Critical patent/JP7772733B2/ja
Application granted granted Critical
Publication of JP7316222B2 publication Critical patent/JP7316222B2/ja
Priority to JP2025076268A priority patent/JP2025111770A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563255A 2017-05-15 2018-05-15 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法 Active JP7316222B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023063333A JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US62/506,494 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US62/536,966 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US62/582,186 2017-11-06
US201862648240P 2018-03-26 2018-03-26
US62/648,240 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023063333A Division JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020519676A JP2020519676A (ja) 2020-07-02
JP2020519676A5 true JP2020519676A5 (https=) 2021-07-26
JP7316222B2 JP7316222B2 (ja) 2023-07-27

Family

ID=64274790

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563255A Active JP7316222B2 (ja) 2017-05-15 2018-05-15 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2023063333A Active JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A Pending JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023063333A Active JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A Pending JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Country Status (10)

Country Link
US (2) US12036283B2 (https=)
EP (1) EP3624827A4 (https=)
JP (3) JP7316222B2 (https=)
KR (2) KR20250057110A (https=)
CN (2) CN119700941A (https=)
AU (2) AU2018270926C1 (https=)
CA (1) CA3060410A1 (https=)
IL (2) IL270634B2 (https=)
MX (2) MX2019013621A (https=)
WO (1) WO2018213341A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020097556A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
EP3946426A4 (en) * 2019-04-05 2023-01-04 Nektar Therapeutics METHOD OF ENHANCING CELLULAR IMMUNOTHERAPY
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
IL288210B2 (en) 2019-05-20 2026-03-01 Cytune Pharma Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
CN117597355A (zh) 2021-06-23 2024-02-23 赛腾制药 白细胞介素15变体
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
IL322075A (en) * 2023-02-14 2025-09-01 Akron Bioproducts Llc Pharmaceutical compositions of interleukin for use in vivo
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1096595A (en) 1993-11-12 1995-05-29 Gilead Sciences, Inc. Thrombin mutants
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
GEP20084487B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
TW200613552A (en) 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Il−15によるb細胞増殖の増強
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
PL2431741T3 (pl) 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2016060996A2 (en) * 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Similar Documents

Publication Publication Date Title
JP2020519676A5 (https=)
JP2020514300A5 (https=)
US8945527B2 (en) Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
JP2021515083A5 (https=)
JP2019534308A5 (https=)
JP2020063241A5 (https=)
JP2020537501A5 (https=)
Xu et al. Immunologically effective poly (D-lactic acid) nanoparticle enhances anticancer immune response
US20130331517A1 (en) Novel Polymer Derivative Of Cytidine Metabolic Antagonist
JP2017526704A5 (https=)
JP2016506916A5 (https=)
JP2015532295A5 (https=)
JP2016529321A5 (https=)
JP2011530597A5 (https=)
JP2006508091A5 (https=)
CN1708540A (zh) 喜树碱的高分子衍生物
JP2010531879A5 (https=)
CN111514306B (zh) 一种增强抗肿瘤免疫治疗的富勒烯纳米颗粒
JP2022526408A5 (https=)
KR20210142663A (ko) 암을 치료하기 위하여 iRGD와 공동 투여되는 저용량 사이토카인
JP2020515688A5 (https=)
US9890245B2 (en) Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol
AU2019392742B2 (en) Anti-cancer activity of adamantane derivatives
JP2018530568A5 (https=)
JP5505261B2 (ja) 薬物伝達用ポリ(アミドアミン)オリゴマーヒドロゲルおよびそれを用いた薬物伝達体